As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.29 · Revenue $27.19M · 3 analysts
Est. EPS $0.02 · Revenue $55.40M · 3 analysts
Est. EPS $-0.94 · Revenue $147.25M · 5 analysts
Est. EPS $-0.31 · Revenue $37.97M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $134.5M | -3.9% | +9.2% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-38.9M | -41.8% | +23.8% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +76.6% | +8.3% | +0.9% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -35.8% | -36.0% | +29.3% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -29.0% | -47.6% | +30.3% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-19.3M | +13.6% | +1.3% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -14.4% | +10.1% | +9.7% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 4.0% | -8.4% | -0.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 10.95x | -3.6% | -60.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $311.8M | -2.1% | +16.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.95 vs -1.05 | +9.8% | -0.29 vs -0.29 | -0.1% |
| Revenue Surprise | $134.5M vs $131.6M | +2.2% | $33.7M vs $27.2M | +24.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Kurtz Ronald M MD | officer: Chief Medical Officer | Common Stock | D | 5,100 | $6.96 |
| Sep 2, 2026 | Wilterding Mark | officer: Chief Financial Officer | Common Stock | D | 7,765 | $6.96 |
| Sep 2, 2026 | Goldshleger Ilya | officer: Chief Operating Officer | Common Stock | D | 2,041 | $6.96 |
| Sep 2, 2026 | Weinberg Eric | officer: See remarks | Common Stock | D | 2,041 | $6.96 |
| Aug 31, 2026 | Kurtz Ronald M MD | officer: Chief Medical Officer | Common Stock | A | 13,425 | — |
Operator: Thank you for standing by, and welcome to the RxSight Second Quarter 2026 Earnings Conference. [Operator Instructions] I would now like to turn the conference over to Oliver Moravcevic, VP of Investor Relations. Oliver Moravcevic: Thank you, operator. With me on the call today are RxSight President and Chief Executive Officer, Aziz Mottiwala, and Chief Financial Officer, Mark Wilterding. Earlier today, RxSight released financial results for the 3 months ended June 30, 2026. A copy of the press release is available now on the company's website. Before we begin, I would like to remind you that comments and responses to questions during today's call reflect management's views as of today and will include forward-looking and opinion statements, including predictions, estimates, plans, and expectations. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued today and in our filings with the Securities and Exchange Commission or SEC. Our SEC filings can be found on our website or the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements, and we disclaim any obligation to update or revise these forward-looking statements except as may be required by law. We'll also discuss certain non-GAAP financial measures. Disclosures regarding non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, which can be found in the press release. Please note that this conference call will be available for audio replay on our Investor Relations website. With that, I will turn the call over to Aziz. Aziz Mottiwala: Thank you, Oliver, and thank you, and good afternoon, everyone. I'm delighted to be at RxSight and to be speaking with you today. I've spent most of my career in eye care, an area of health care that represents a significant opportunity to make life-changing differences in the quality of patients' lives. Joining a company dedicated to improving people's vision is a tremendous privilege, and in a large part is what attracted me to RxSight. Most recently, as Chief Commercial Officer of Tarsus Pharmaceuticals, I helped build and lead the commercial strategy for one of the most important category-creating products in eye care. That experience reinforced the importance of differentiated innovation, disciplined execution, and strong customer engagement. I look forward to leveraging those experiences as we work to strengthen execution and create value for physicians, patients, employees, and shareholders. I'd like to thank the board of directors for placing its confidence in me, and I also want to acknowledge the entire RxSight team. Over the past 2 weeks, everyone has been incredibly welcoming, and I've been impressed by the spirit of innovation, level of commitment, and problem-solving mindset across the organization. That doesn't …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Eric J. Weinberg | Chief Business Development Officer | USD 2,746,290 | Male | 1961 | Active |
Mark Wilterding | Chief Financial Officer | USD 877,380 | Male | 1978 | Active |
Aziz Mottiwala | President, Chief Executive Officer & Director | USD 834,131 | Male | 1978 | Active |
Ronald Kurtz | Chief Medical Officer | USD 834,131 | — | 1963 | Active |
Ilya Goldshleger | Chief Operating Officer | USD 634,007 | — | 1975 | Active |
Adam Dashe | Executive Vice President of International | — | Male | — | Active |
Patrick Cullen | Executive Vice President of Quality & Infrastructure Operations | — | Male | — | Active |
Maureen O'Connell | Executive Vice President of Clinical & Regulatory Affairs | — | Female | — | Active |
Trent Campbell | Executive VP of US Sales & Commercial Strategy | — | Male | — | Active |
Oliver Moravcevic | Vice President of Investor Relations | — | Male | — | Active |
Jim Schindler | Executive VP & General Counsel | — | Male | — | Active |
BlackRock Inc. acquired a new stake in RxSight, Inc. (NASDAQ: RXST) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,790,408 shares of the company's stock, valued at approximately $27,910,000. BlackRock Inc. owned 13.99% of RxSight at the end
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/.
RxSight (NASDAQ: RXST - Get Free Report) and Futureworld (OTCMKTS:FWDG - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Risk and Volatility RxSight has a beta of 1.13, suggesting
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight NASDAQ: RXST reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business.
